The Living Guidelines: UA/NSTEMI Recommendations for UA/NSTEMI in Women Suggest Revisions to the CLASS I Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Instructions on How to Edit the Guidelines:
 * Log in
 * Click on "Edit"
 * Type in changes to guidelines
 * Click "Save page" at the bottom of the page

Class I Guidelines

 * 1) Women with UA / NSTEMI should be managed with the same pharmacological therapy as men both in the hospital and for secondary prevention, with attention to antiplatelet and anticoagulant doses based on weight and renal function; doses of renally cleared medications should be based on estimated creatinine clearance. (Level of Evidence: B)
 * 2) Recommended indications for noninvasive testing in women with UA / NSTEMI are similar to those for men. (Level of Evidence: B)
 * 3) For women with high-risk features, recommendations for invasive strategy are similar to those of men (Level of Evidence: B)
 * 4) In women with low-risk features, a conservative strategy is recommended. (Level of Evidence: B)